Cargando…
Distinct pro-vigilant profile induced in rats by the mGluR5 potentiator LSN2814617
While treatment options are available, excessive daytime sleepiness (EDS) remains a significant unmet medical need for many patients. Relatively little rodent behavioural pharmacology has been conducted in this context to assess potential pro-vigilant compounds for their ability to restore functiona...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600478/ https://www.ncbi.nlm.nih.gov/pubmed/25902875 http://dx.doi.org/10.1007/s00213-015-3936-8 |
_version_ | 1782394425929891840 |
---|---|
author | Loomis, Sally McCarthy, Andrew Baxter, Christopher Kellett, Daniel O. Edgar, Dale M. Tricklebank, Mark Gilmour, Gary |
author_facet | Loomis, Sally McCarthy, Andrew Baxter, Christopher Kellett, Daniel O. Edgar, Dale M. Tricklebank, Mark Gilmour, Gary |
author_sort | Loomis, Sally |
collection | PubMed |
description | While treatment options are available, excessive daytime sleepiness (EDS) remains a significant unmet medical need for many patients. Relatively little rodent behavioural pharmacology has been conducted in this context to assess potential pro-vigilant compounds for their ability to restore functional capacity following experimentally induced sleep loss. Male Wistar rats were prepared for electroencephalographic (EEG) recording and subject to 11 h of sleep restriction using a biofeedback-induced cage rotation protocol. A simple response latency task (SRLT) was used to behaviourally index sleep restriction and the effects of pro-vigilant compounds: modafinil, d-amphetamine, caffeine, and the mGlu5-positive allosteric modulator LSN2814617. Sleep restriction resulted in a consistent, quantified loss of non-rapid eye movement (NREM) and REM sleep that impaired SRLT performance in a manner suggestive of progressive task disengagement. In terms of EEG parameters, all compounds induced wakefulness. Amphetamine treatment further decreased SRLT performance capacity, whereas the other three compounds decreased omissions and allowed animals to re-engage in the task. Caffeine and modafinil also significantly increased premature responses during this period, an effect not observed for LSN2814617. While all compounds caused compensatory sleep responses, the magnitude of compensation observed for LSN2814617 was much smaller than would be predicted to result from the prolongation of wakefulness exhibited. Using simple response latencies to index performance, an mGlu5 PAM dramatically increased wakefulness and improved functional capacity of sleep-restricted animals, without eliciting a proportionate compensatory sleep response. This effect was qualitatively distinct from that of amphetamine, caffeine and modafinil. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00213-015-3936-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4600478 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-46004782015-10-16 Distinct pro-vigilant profile induced in rats by the mGluR5 potentiator LSN2814617 Loomis, Sally McCarthy, Andrew Baxter, Christopher Kellett, Daniel O. Edgar, Dale M. Tricklebank, Mark Gilmour, Gary Psychopharmacology (Berl) Original Investigation While treatment options are available, excessive daytime sleepiness (EDS) remains a significant unmet medical need for many patients. Relatively little rodent behavioural pharmacology has been conducted in this context to assess potential pro-vigilant compounds for their ability to restore functional capacity following experimentally induced sleep loss. Male Wistar rats were prepared for electroencephalographic (EEG) recording and subject to 11 h of sleep restriction using a biofeedback-induced cage rotation protocol. A simple response latency task (SRLT) was used to behaviourally index sleep restriction and the effects of pro-vigilant compounds: modafinil, d-amphetamine, caffeine, and the mGlu5-positive allosteric modulator LSN2814617. Sleep restriction resulted in a consistent, quantified loss of non-rapid eye movement (NREM) and REM sleep that impaired SRLT performance in a manner suggestive of progressive task disengagement. In terms of EEG parameters, all compounds induced wakefulness. Amphetamine treatment further decreased SRLT performance capacity, whereas the other three compounds decreased omissions and allowed animals to re-engage in the task. Caffeine and modafinil also significantly increased premature responses during this period, an effect not observed for LSN2814617. While all compounds caused compensatory sleep responses, the magnitude of compensation observed for LSN2814617 was much smaller than would be predicted to result from the prolongation of wakefulness exhibited. Using simple response latencies to index performance, an mGlu5 PAM dramatically increased wakefulness and improved functional capacity of sleep-restricted animals, without eliciting a proportionate compensatory sleep response. This effect was qualitatively distinct from that of amphetamine, caffeine and modafinil. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00213-015-3936-8) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2015-04-24 2015 /pmc/articles/PMC4600478/ /pubmed/25902875 http://dx.doi.org/10.1007/s00213-015-3936-8 Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Investigation Loomis, Sally McCarthy, Andrew Baxter, Christopher Kellett, Daniel O. Edgar, Dale M. Tricklebank, Mark Gilmour, Gary Distinct pro-vigilant profile induced in rats by the mGluR5 potentiator LSN2814617 |
title | Distinct pro-vigilant profile induced in rats by the mGluR5 potentiator LSN2814617 |
title_full | Distinct pro-vigilant profile induced in rats by the mGluR5 potentiator LSN2814617 |
title_fullStr | Distinct pro-vigilant profile induced in rats by the mGluR5 potentiator LSN2814617 |
title_full_unstemmed | Distinct pro-vigilant profile induced in rats by the mGluR5 potentiator LSN2814617 |
title_short | Distinct pro-vigilant profile induced in rats by the mGluR5 potentiator LSN2814617 |
title_sort | distinct pro-vigilant profile induced in rats by the mglur5 potentiator lsn2814617 |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600478/ https://www.ncbi.nlm.nih.gov/pubmed/25902875 http://dx.doi.org/10.1007/s00213-015-3936-8 |
work_keys_str_mv | AT loomissally distinctprovigilantprofileinducedinratsbythemglur5potentiatorlsn2814617 AT mccarthyandrew distinctprovigilantprofileinducedinratsbythemglur5potentiatorlsn2814617 AT baxterchristopher distinctprovigilantprofileinducedinratsbythemglur5potentiatorlsn2814617 AT kellettdanielo distinctprovigilantprofileinducedinratsbythemglur5potentiatorlsn2814617 AT edgardalem distinctprovigilantprofileinducedinratsbythemglur5potentiatorlsn2814617 AT tricklebankmark distinctprovigilantprofileinducedinratsbythemglur5potentiatorlsn2814617 AT gilmourgary distinctprovigilantprofileinducedinratsbythemglur5potentiatorlsn2814617 |